R&D News | pharmaphorum

News

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

News

Finland's GlucoModicum thinks it is in the lead in the race to bring a non-invasive continuous glucose monitor (CGM) to market.

News

Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.

News

AstraZeneca chief executive Pascal Soriot is reportedly considering moving the company's stock exchange listing from the UK to the US.

News

The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.

News

Four years after buying Five Prime for $1.9bn, Amgen has promising phase 3 results with a gastric cancer drug that was the focal point for the deal.